EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Evolus, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.36+0.26 (+3.66%)
Close on Oct 19, 2026
- Market cap
- $485.24M
- P/E (TTM)
- –
- Dividend yield
- –
Evolus, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $314.28M | $299.63M | $294.96M | $284.70M | $275.89M | $273.42M | $264.31M | $246.02M | $235.18M | $217.64M | $199.72M | $182.04M | 99.3% | +13.9% |
| Service revenue | $2.21M | $2.16M | $2.22M | – | – | – | – | $2.31M | $2.08M | $2.06M | $2.36M | $2.69M | 0.7% | – |
By region
From the segment and revenue-disaggregation notes of Evolus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.